ClinicalTrials.gg
CompletedNCT03599284Updated Sep 23, 2019

The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel

A Phase 2 interventional study of Vicagrel 5mg and Vicagrel 6mg in Coronary Artery Disease, Percutaneous Coronary Intervention and Platelet Aggregation Inhibitors, sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Completed at 27 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-23.

Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
279
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 543 studies in Coronary Artery Disease with a site in China — 176 open to participants now, 210 under way, 6 of them phase 3. Coronary Artery Disease · China.

Enrollment
175th of 324
279 · median 307
Started
2018
with 38 others
Phase 2
12 of 543
4 open now
Registered
183rd of 543
by date

Among the 543 studies in Coronary Artery Disease with a site in China, this one is the 175th largest by enrollment of the 324 interventional ones that give a count, is one of 39 that started in 2018, is one of 12 in phase 2, and was the 183rd registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

176 of the 543 studies in Coronary Artery Disease with a site in China are open now. Recruiting first, the newest first:

171 more — sign in →

All 176 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 543 studies in Coronary Artery Disease with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, triple-dummy, parallel-controled, dose-exploration phase II trial. Patients with coronary atherosclerotic heart disease and planned percutaneous coronary intervention (PCI) will be randomized after informed consent, in a 1:1:1:1 ratio to the following treatment groups: Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days; Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days; Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days; Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days. The primary purpose of this trial is to evaluate the efficacy, safety of vicagrel antiplatelet therapy and explore dose in patients with coronary atherosclerotic heart disease during and after PCI compared with clopidogrel.

03

Conditions studied

  • Coronary Artery Disease
  • Percutaneous Coronary Intervention
  • Platelet Aggregation Inhibitors
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female aged 18-75.
  • Weight ≥ 50 kg
  • Patients with coronary atherosclerotic heart disease diagnosed clinically and planned percutaneous coronary intervention
  • Patients with ability and willingness to sign and adherence to trial protocol.

Exclusion criteria

Exclusion Criteria:

  • Hemorrhagic symptoms (such as hematemesis, melena, severe or recurrent epistaxis, hemoptysis, marked hematuria, gastrointestinal bleeding, or intracranial hemorrhage), or suspected vascular malformations (such as aneurysms), or abnormal bleeding history (such as abnormal hemorrhage attributed to tooth extraction), himself or his immediate family with coagulation or bleeding disorders (such as hemophilia);
  • Non-ST-segment elevation acute coronary syndrome (\<2h emergency PCI), or ST-segment elevation myocardial infarction within 7 days;
  • Patients with suspected aortic dissection;
  • Patients with negative coronary Computed Tomography angiography(CTA)(coronary CTA depending on investigator);
  • Patients with severe disease and \<1 year;
  • Patients with acute peptic ulcer;
  • History of hemorrhagic stroke or history of ischemic stroke within 6 months before screening and a definite diagnosis of structural abnormalities in the central nervous system;
  • Patients with uncontrolled high blood pressure (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg) after drug treatment during screening;
  • One of the following conditions: cardiogenic shock, chronic congestive heart with failure (NYHA) grade ≥ III grade or determined by echocardiography \< 35%, hypotension (systolic pressure \< 90 mmHg and or diastolic pressure \< 60 mmHg), severe arrhythmias (including high-degree atrioventricular block, sick sinus syndrome, persistent ventricular tachycardia), severe pulmonary insufficiency, pulmonary embolism, and hepatic insufficiency ( or AST caused by non-cardiac diseases exceeding the by more than 3 times), severe renal insufficiency ( \< 30 ml/min), cirrhosis;
  • Patients Received P2Y12 receptor antagonist and Ⅱb/IIIa receptor inhibitor, oral anticoagulant (warfarin, rivaroxaban, dabigatran, etc.) within 14 days before screening;
  • Prolonged cardiopulmonary resuscitation (more than 10 minutes) or severe trauma within 2 weeks before screening;
  • Patients plan to undergo another surgery within 1 month after participating in this trial,or plan to undergo PCI procedure performed several times during the test (except for the end of the safety follow-up);
  • History of severe allergies, non-allergic drug reactions or allergies to 2 or more drugs (including contrast agents), or known allergies to the similar drugs (clopidogrel, ticagrelor) as the study drug or of aspirin;
  • Patients with mental disorders or alcohol dependence;
  • Patients being receiving any experimental medicine or experimental medical devices;
  • (PT)> 1.3 times the upper limit of normal or international normalized ratio (INR)> 2.0;
  • count (PLT) \< 100×10\^9/L or > 600×10\^9/L;
  • \< 10g/dL;
  • Patients who cannot tolerate dual antiplatelet therapy for 28 days;
  • Female of reproductive age with positive blood pregnancy test;
  • Female with gestational intention or in lactation;
  • Other unsuitable conditions considered by investigators.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
279 participants (actual)

Study arms

  • Experimental
    Experimental group 1

    Experimental group 1: Vicagrel 20mg loading followed by 5mg/day for 28 days

    Drug: Vicagrel 5mg

  • Experimental
    Experimental group 2

    Experimental group 2: Vicagrel 24mg loading followed by 6mg/day for 28 days

    Drug: Vicagrel 6mg

  • Experimental
    Experimental group 3

    Experimental group 3: Vicagrel 30mg loading followed by 7.5mg/day for 28 days

    Drug: Vicagrel 7.5mg

  • Active comparator
    Control group

    Control group: Clopidogrel 300mg loading followed by 75mg/day for 28 days

    Drug: Clopidogrel 75mg

Interventions

  • Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days

  • Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days

  • Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days

  • Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days

06

What researchers measure

Primary outcomes

  1. Inhibition of platelet aggregation

    Inhibition of platelet aggregation will be assessed by Verifynow System

    Time frame: 28 days after treatment

07

Study locations

27 sites
  • First Affiliated Hospital Bengbu Medical College
    Bengbu, Anhui 233004, China
  • Beijing Anzhen Hospital, Capital Medical Universily
    Beijing, Beijing 100029, China
  • Guangdong General Hospital
    Guangzhou, Guangdong 510030, China
  • First Affiliated Hospital of Zhongshan University
    Guangzhou, Guangdong 510080, China
  • First Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050100, China
  • Wuhan Asia Heart Hospital
    Wuhan, Hubei 430022, China
  • Changsha Central Hospital
    Changsha, Hunan 410004, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan 410008, China
  • Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
  • Affiliated Drum Tower Hospital of Nanjing University Medical School
    Nanjing, Jiangsu 210008, China
  • Zhongda Hospital of Southeast University
    Nanjing, Jiangsu 210009, China
  • Jiangxi Provincial People's Hospital
    Nanchang, Jiangxi 330006, China
  • First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Second Hospital of Jilin University
    Changchun, Jinin 130041, China
  • the General Hospital of Shenyang Military Region of The Chinese People's Liberation Army(The General Hospital of Shenyang Military)
    Shenyang, Liaoning 110015, China
  • The People's Hospital of Liaoning Province
    Shenyang, Liaoning 110015, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110134, China
  • Qinghai Provincial People's Hospital
    Xining, Qinghai 810007, China
  • Yuncheng Central Hospital
    Yuncheng, Shanxi 044000, China
  • Affiliated Hospital of Southwest Medical University
    Luzhou, Sichuan 646000, China
  • Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
  • Sir Run Run Shaw Hospital
    Hangzhou, Zhejiang 310020, China
  • China-Japan Friendship Hospital
    Beijing, 100029, China
  • Peking Union Medical College Hospital
    Beijing, 100032, China
  • Tianjin Medical University General Hospital
    Tianjing, 300052, China
  • Tianjin People's Hospital
    Tianjin, 300121, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Jun 2019, 9 months.

Of 26 industry-sponsored phase 2 interventional studies under Coronary Artery Disease, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 29. This study's 9 months is below that.

Counting every sponsor, half of 55 studies reached it within 28 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2018
First posted
Jul 26, 2018
StartActual
Aug 30, 2018
Primary completionActual
Jun 11, 2019
CompletionActual
Jul 28, 2019
Last update
Sep 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03599284
Responsible party
Sponsor
First posted
Jul 26, 2018
Start date
Aug 30, 2018
Primary completion
Jun 11, 2019
Completion
Jul 28, 2019
Last update
Sep 23, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sumecigrel

Start the discussion